GLP1R and diabetes mellitus: The diabetes therapeutic landscape has been dominated in past years by glucagon-like peptide-1 receptor agonists (GLP-1 RA) and SGLT2i, medications that have demonstrated multiple metabolic, cardiovascular, renal, and possible neurological benefits [66,67,68].